{"schema_version":"secwatch.filing_event.v1","accession":"0001161697-23-000441","form_type":"8-K","ticker":"KRMD","cik":"0000704440","company_name":"KORU Medical Systems, Inc.","filed_at":"2023-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.445527+00:00","generated_at":"2026-06-11T23:44:28.407807+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"KORU Medical Q2 revenue $6.9M (+6% YoY); cuts FY2023 revenue guidance to $31.0-32.5M","bullets":["Q2 net revenue $6.9M (+6% YoY); Domestic Core +8%, International Core +17%.","Net loss $2.5M ($0.05/sh) improved from $2.9M loss ($0.07/sh) prior year; gross margin 56.1%.","Cuts FY2023 revenue guidance to $31.0-32.5M (11-17% growth) from prior $32.5-33.5M (17-20% growth).","Appoints Tom Adams as CFO; submitted 510(k) for FREEDOM60 with Hizentra prefilled syringes.","Reaffirms FY2023 gross margin 58-60% and year-end cash >$10.0M."],"urls":{"canonical":"https://secwatch.observer/filing/0001161697-23-000441","json":"https://secwatch.observer/filing/0001161697-23-000441.json","markdown":"https://secwatch.observer/filing/0001161697-23-000441.md","text":"https://secwatch.observer/filing/0001161697-23-000441.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/704440/000116169723000441/0001161697-23-000441-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/704440/000116169723000441/form_8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T23:44:28.407807+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"547656231bfd9b822bc7692b8c72c22ddc9092d3","claim":"KORU Medical Systems, Inc. reported the second quarter ended June 30, 2023 results: revenue $6,935,930, net income $ 2.5 million, EPS $(0.05) per diluted share.","evidence_excerpt":"2023 Second Quarter Financial Results Three Months Ended June 30, Change from Prior Year 2023 2022 $ % Net Revenues Domestic Core $ 5,388,172 $ 4,996,791 $ 391,381 $ 7.8% International Core 1,117,004 951,485 165,519 17.4% Novel Therapies 430,754 598,352 (167,598 ) (28.0)% Total $ 6,935,930 $ 6,546,628 $ 389,302 $ 5.9% Total net revenue increased $0.4 million, or 6%, for the three months ending June 30, 2023, compared to last year. Domestic Core growth of 8% was primarily driven by increased growth in consumables and pumps, new accounts, and increased prefilled syringe adoption. International Core growth of 17% was driven by strength across several EU markets, and growing global immunoglobulin drug volume availability. Novel Therapies net revenue declined by 28% in primarily related to strong non-recurring engineering revenues in the comparable quarter last year as well as the timing of 2023 pipeline wins. Gross profit increased $0.5 million or 16% in the three months ended June 30, 202","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/704440/000116169723000441/0001161697-23-000441-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Revenue","value":"$6,935,930"},{"label":"Net income","value":"$ 2.5 million"},{"label":"EPS","value":"$(0.05) per diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"d40329a1b0b80d1f5f3585c306916805e45d7db9","claim":"KORU Medical Systems, Inc. reported full year 2023 results: revenue $31.0 - $32.5 million. Guidance lowered.","evidence_excerpt":"Reducing full year 2023 net revenue guidance to $31.0 and $32.5 million, representing growth in the range of 11%-17% from prior guidance of $32.5 - $33.5 million, representing growth in the range of 17-20% ● Reaffirming 2023 gross margin between 58%-60% and a planned 2023 exit between 60%-62% ● Reaffirming cash balance at year-end 2023 greater than $10.0 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/704440/000116169723000441/0001161697-23-000441-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year 2023"},{"label":"Revenue","value":"$31.0 - $32.5 million"},{"label":"Guidance","value":"lowered"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}